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Objective To investigate the efficacy and safety of selective head cooling with mild systemic hypothermia in
hypoxic-ischemic encephalopathy (HIE) in newborn infants.
Study design Infants with HIE were randomly assigned to the selective head cooling or control group. Selective
head cooling was initiated within 6 hours after birth to a nasopharyngeal temperature of 34  0.2C and rectal tem-
perature of 34.5 to 35.0C for 72 hours. Rectal temperature was maintained at 36.0 to 37.5C in the control group.
Neurodevelopmental outcome was assessed at 18 months of age. The primary outcome was a combined end point
of death and severe disability.
Results One hundred ninety-four infants were available for analysis (100 and 94 infants in the selective head cool-
ing and control group, respectively). For the selective head cooling and control groups, respectively, the combined
outcome of death and severe disability was 31% and 49% (OR: 0.47; 95% CI: 0.26-0.84; P = .01), the mortality rate
was 20% and 29% (OR:0.62; 95% CI: 0.32-1.20; P = .16), and the severe disability rate was 14% (11/80) and 28%
(19/67) (OR: 0.40; 95% CI: 0.17-0.92; P = .01).
Conclusions Selective head cooling combined with mild systemic hypothermia for 72 hours may significantly de-
crease the combined outcome of severe disability and death, as well as severe disability. (J Pediatr 2010;157:367-72).See editorial, p 351 and related
articles, p 361 and p 499H
ypoxic-ischemic encephalopathy (HIE) remains a major cause of neonatal death and long-term disabilities.1,2 Although
there has been tremendous progress in neonatal care, management strategies that minimize the morbidity of HIE have
been limited. Data from animal studies showed protective effects of mild hypothermia to immature brain,3,4 and the
critical timing for mild hypothermia was within 6 hours after hypoxic-ischemic injury and for a period of 24 to 72 hours.3,5-8
Gunn et al9 reported a pilot study of mild hypothermia for HIE in 1998. Since then, several studies have shown a trend for brain
protection with mild to moderate hypothermia.10-15 Three multicenter randomized controlled trials (RCTs) were published
currently,16-18 and another 3 RCTs are being completed or have been completed including ICE Trial (Australian), neo.nEur-
o.network Trial (European)19, 20 and this study.
Since 1998, research about the neuroprotective effect of mild hypothermia for HIE has been performed in China.21-26 We
reported a pilot study to investigate the efficacy and safety of selective head cooling in HIE newborn infants in 2002 that showed
that selective head cooling was safe, simple, useful, and effective.27 Reassured by our results, we organized a multicenter RCT of
selective head cooling combined with mild systemic hypothermia to treat in infants with HIE.HIE
RCTMethodsFrom the Children’s Hospital of Fudan University,
Shanghai (W.Z., G.C., X.S., Y.C., Q.Y., L.W.), Guangxi
Maternity and Infant Health Hospital, Guangxi Province
(X.L.), Qingdao Children’s Hospital, Shandong Province
(R.S.), Quanzhou Children’s Hospital, Fujian Province
(D.Z.), The First Hospital of Beijing University, Beijing
(C.Z.), and Children’s Hospital of Zhejiang University,
Zhejiang Province (L.D.), China
*A list of members of The China Study Group is available
at www.jpeds.com (Appendix).This study involved the participation of 12 children’s hospitals or children’s and
women’s health care centers. The protocol was designed by the neonatologists at
Children’s Hospital of Fudan University and a consensus was reached by the par-
ticipating hospitals. Written informed consent was obtained from parents before
enrollment. This study was approved by the ethics committee of the Children’s
Hospital of Fudan University.
Infants were screened for eligibility if they had a gestational age $ 37 weeks
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THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 157, No. 3unit within 6 hours of age with clinical evidence of exposure
to perinatal hypoxia-ischemia or a diagnosis of encephalop-
athy. Inclusion criteria were as follow: an Apgar score #3 at 1
minute and #5 at 5 minutes; cord blood gas pH <7.0 or base
deficit #16 mmol/L; and need for resuscitation or ventilation
at 5 minutes of age. Eligible infants then underwent a stan-
dardized neurologic examination performed by a certified
examiner. The severity of HIE (mild, moderate and severe)
was assessed according to criteria of Sarnat and Sarnat,28 in-
cluding lethargy, stupor, or coma, with 1 or more of the find-
ings of hypotonia, abnormal reflexes, or clinical seizure.
Exclusion criteria were as follow: (1) Major congenital ab-
normalities; (2) Infection (rupture of membranes >18 hours
or maternal fever >38C or amniotic fluid foul smell); (3)
Other encephalopathy (neonatal stroke, central nervous system
abnormality, intracranial hemorrhage diagnosed by CT or head
ultrasonography); (4) Severe anemia (hemoglobin <120 g/L).
The randomization codes were generated by computer and
supplied in numbered, sealed opaque envelopes. After in-
formed consent was obtained from a parent, the assignment
to a treatment or control group was performed by telephone.
Assignments were stratified according to center in a random-
ized block design with a block size of 6.
The Procedure for Selective Head Cooling and
Temperature Monitoring
A semiconductor controlled water circulation cooling device
(YJW608-04B; Henyang Radio Manufactory, Hunan, China)
was used for head cooling. Infants were fitted with a cooling
cap around the head. The temperature of the cap could be reg-
ulated by a servocontrolled temperature probe placed in the na-
sopharynx to maintain the nasopharyngeal temperature at
(34  0.2C). Infants were nursed under a radiant warmer,
which was servocontrolled to the infant’s abdominal skin tem-
perature and adjusted to maintained rectal temperature at
34.5 to 35C. Head cooling was started within 6 hours of
age and continued for 72 hours, followed by spontaneous re-
warming. Infants in the control group were cared for on radiant
warmers, which were servocontrolled to the infant’s abdominal
skin temperature to maintained rectal temperature at 36 to
37.5C. Infants in both groups received the same clinical care
and monitoring of vital signs and surveillance for organ dys-
function aside from selective head cooling or normothermia.
Ventilation, inotropes, anticonvulsant medications, and
mannitol (if infants had bulging fontanelle or status epilepti-
cus) were used as required. Both groups received total paren-
teral nutrition, and oral feeding was started by 3 days of age.
Monitoring
Nasopharyngeal and rectal temperature, oxygen saturation,
respiratory rate, heart rate and blood pressure were moni-
tored with the Siemens-SC6000 monitor (Siemens, Berlin,
Germany) in both groups. We measured blood gases, electro-
lytes, blood glucose, liver function tests, renal function tests,
and complete blood count according to a standardized pro-
tocol(before treatment, 12 hours, 24 hours, 48 hours,72
hours after treatment). Blood gas measurements were cor-368rected for body temperature. Electrocardiography was per-
formed if bradycardia of less than 80 beats/min or
arrhythmia was suspected.
Adverse Events
We defined major adverse events as severe arrhythmia (II or
III degree A-V block or atrial or ventricular arrhythmia), ma-
jor venous thrombosis (ie, thrombosis of a major vessel not
related to an infusion line), refractory hypotension (mean
blood pressure less than 40 mm Hg despite full support),
moderate or severe scleredema (greater or equal to 20%
body surface area),29 and severe bleeding (disseminated in-
travascular coagulation, lung hemorrhage, gastrointestinal
hemorrhage and gross hematuria).
We defined common adverse events as mild arrhythmia
(sinus bradycardia if heart rate <80 beats/min, prolonged
QT interval, occasional premature beats, and I degree A-V
block), mild scleredema (less than 20% body surface area),
renal dysfunction (creatinine >120 mmol/L, blood urea nitro-
gen >8 mmol/L or urine output <1 mL/kg/h), liver dysfunc-
tion (alanine transaminase >100 U/L), thrombocytopenia
(platelet <100  109/L), serum electrolytes or biochemical
abnormalities (sodium <130 mmol/L or >150 mmol/L, po-
tassium <3.5 mmol/L or >5.5 mmol/L, calcium <2.0
mmol/L, blood glucose >8 mmol/L or <2.6 mmol/L).
Follow-Up
The primary outcome was the combined endpoint of death
and severe disability at 18 months of age. Survivors returned
for follow-up had a neurologic examination by certified staff
blinded to the treatment group, and a neurodevelopmental
assessment with the Gesell Child Development Age Scale30
and the Gross Motor Function Classification System
(GMFCS).31 GMFCS level 3-5 or DQ <70 were defined as se-
vere disability. For infants who did not return for follow-up,
we obtained information on neurodevelopment outcomes
assessed by the trained pediatrician in local child health
care or rehabilitation department.
Statistical Analysis
The baseline mortality or severe disability rate in the control
group was estimated at 50%. To detect an absolute decrease
of 20% to 30% in the selective head cooling group, with a 2-
sided test with an alpha of 0.05 and power of 80%, and an es-
timated 20% loss to follow-up, 228 (114 in each group) pa-
tients were needed.
All data analyses were performed according to the intention-
to-treat principle. Mean  SD was used for normally distrib-
uted data. Between-group comparisons of continuous vari-
ables were conducted with the Student t test. Proportions are
presented as percentages, and between-group comparisons
were conducted with c2 test or Fisher exact test. Multinomial
logistic regression was done incorporating the sex, seizure,
and fever variables. An external data and safety monitoring
committee monitored safety and efficacy during analyses.
SPSS 13.0 (SPSS, Inc., Chicago, Illinois) was used for statistical
analysis. Alpha set at 0.05, and all tests were 2-tailed.Zhou et al





(n = 94) P
Major adverse events 3 (3%) 3 (3.2%) 1
Major cardiac arrhythmia 0 1 (1.1%) .49
September 2010 ORIGINAL ARTICLESResults
From May 2003 to August 2005, a total of 256 cases were re-
cruited. Figure 1 (available at www.jpeds.com) shows the
trial profile. Twenty-one infants (19 and 2 infants in the
selective head cooling and control group) were excluded
because the pediatricians in the local hospitals did not
follow the scheduled random methods.
Characteristics and Monitoring of Infants
There were no statistically significant differences in baseline
characteristics (Table I). The average time of onset of
treatment was 4.1  1.2 hours after delivery in the selective
head cooling group, of which 61 cases (51.2%) were started
within 4 hours. The average time to reach the target
nasopharyngeal temperature was about 2 hours, and the
nasopharyngeal temperature was maintained about 34C,
and the rectal temperature was maintained between
34.5 and 35.0C during hypothermia. After 72 hours
hypothermia, spontaneous rewarming began, and the
average time to reach 36.5C for rectal temperature was
12.5  6.1 hours. There were no adverse events during the
rewarming period. In the control group, the average value
of nasopharyngeal and rectal temperature was stable and
maintained at about 36C to 36.5C. The changes over
time of the nasopharyngeal and rectal temperatures are
shown in Figure 2, A (available at www.jpeds.com).
Adverse Events
Heart rate decreased on average 20 to 30 beats/min compared
with the control group during hypothermia, but there were
only 4 cases (4%) with heart rates less than 80 beat/min.
The changes over time of heart rate are shown in Figure 2,
B (available at www.jpeds.com). Scalp edema occurred in
22 cooled infants and recovered rapidly after the cooling.




(n = 94) P
Mode of delivery .89
Cesarean 40 (40%) 36 (38%)
Assisted* 24 (24%) 21 (22%)
Spontaneous 36 (36%) 37 (40%)
Male 87 (87%) 78 (83%) .43
Complications of pregnancy 50 (50%) 40 (43%) .3
Fetal distress 73 (73%) 66 (70%) .67
Seizures 49 (49%) 44 (47%) .76
Assist ventilation† 16 (16%) 22 (23%) .2
Transferred from birth hospital 77 (77%) 77 (82%) .4
Severity of HIE .92
Mild 21 (21%) 18 (19%)
Moderate 41 (41%) 41 (44%)
Severe 38 (38%) 35 (37%)
5-minute Apgar score #5 80 (80%) 71 (76%) .46
Birth weight (g) 3360  483 3299  421
Onset of therapy
(hours after birth)
4.1  1.2 4.0  1.7 .19
*Include assisted delivery by forceps and vacuum extraction.
†CPAP: selective head cooling 1, control 3.
Selective Head Cooling with Mild Systemic Hypothermia After Ne
Encephalopathy: A Multicenter Randomized Controlled Trial in Chypothermia, which recovered after rewarming. Death,
major, and other adverse events were similar between the 2
groups (Table II), which means there is no significant
adverse events of hypothermia therapy on neonatal HIE.
Primary and Secondary Outcome
Primary outcome were available for 194 infants, including 5
cases in the selective head cooling and 4 cases in the control
group were assessed by local hospitals. Among the 5 cases in
the selective head cooling group, there were 2 mild and 3
moderate HIE cases without severe disabilities. Among the
4 cases in the control group, there were 1 mild, 2 moderate,
and 1 severe HIE cases, and 2 of the cases had development
of cerebral palsy.
The combined incidence of death and major disability was
lower in the selective head cooling group than that in the control
groups (Table III). Among the 11 infants with disability in the
selective head cooling group, 7 had cerebral palsy, 3 had cerebral
palsy with mental retardation, and 1 had mental retardation.
Nineteen cases in the control group had cerebral palsy, and 13
of these also had mental retardation. We repeated the analysis
after exclusion of the 9 infants whose outcomes were assessed
by telephone communication. The incidence of death or
severe disability was significantly decreased in the selective
head cooling group (33%) compared with the control group
(49%) (OR: 0.51; 95% CI: 0.28-0.92; P = .024).
A total of 138 infants (75 and 63 infants in the selective
head cooling and control group respectively) had the Gesell
Child Development Scale score. The average DQ score wasSevere hemorrhage 3 (3%) 2 (2.1%) .68
Major venous thrombosis 0 0
Complication during 96 of treatments
Raised BUN 23 (23%) 21 (22%) .91
Raised creatinine 21 (21%) 19 (20%) .89
Oliguria 7 (7%) 4 (4.3%) .54
Raised liver enzymes 35 (35%) 26 (28%) .27
Hypocalcemia 40 (40%) 33 (35%) .21
Hypokalemia 10 (10%) 16 (17%) .15
Hyperkalemia 25 (25%) 20 (21%) .54
Hyponatremia 12 (12%) 14 (14.9) .55
Hypoglycemia 7 (7%) 2 (2%) .17
Hyperglycemia 7 (7%) 3 (3%) .33
Metabolic acidosis 7 (7%) 7 (7.4%) .9
Platelet count <100 000 per mL 6 (6%) 2 (2%) .28
Cause of death .88
HIE 7 (35%) 12 (44%)
Respiratory failure 3 (20%) 5 (19%)
Kidney failure 2 (10%) 3 (11%)
Severe hemorrhage 3 (15%) 2 (7%)
Others 5 (25%) 5 (19%)
Distribution of age at death .13
#3 days 8 (40%) 17 (63%)
4-7 days 4 (20%) 6 (22%)
>7 days 8 (40%) 4 (14%)




Table III. Primary and secondary outcomes and components
Head Cooling Control OR (95%CI) P
Primary outcomes
Death or severe disability 31/100 (31%) 46/94 (49%) 0.47 (0.26-0.84) .01
Death 20/100 (20%) 27/94 (29%) 0.62 (0.32-1.20) .16
Severe disability 11/80 (14%) 19/67 (28%) 0.40 (0.17-0.92) .03
Secondary outcomes
Death or severe disability
Infants with moderate to severe HIE 31/79 (39%) 46/76 (61%) 0.42 (0.22-0.80) .01
Infants with moderate HIE 9/41 (22%) 19/41 (46%) 0.33 (0.16-0.85) .02
Infants with severe HIE 22/38 (58%) 27/35 (77%) 0.41 ( 0.15-1.13) .08
Survival with severe disability
Infants with moderate to severe HIE 11/59 (24%) 19/49 (41%) 0.36 (0.15-0.87) .02
Infants with moderate HIE 6/38 (24%) 15/37 (39%) 0.49 (0.18-1.33) .21
Infants with severe HIE 5/21 (24%) 4/12 (33%) 0.63 (0.13-2.99) .18
DQ of total infants*
Median (range) 93 (45-112) 89 (22-115) .045
DQ<70 (%) 4/75 (5%) 13/63 (21%) 0.22 (0.07-0.70) .01
DQ 70-84 (%) 23/75 (31%) 17/63 (27%) 1.2 (0.57-2.51) .64
DQ$85 (%) 48/75 (64%) 33/63 (52%) 1.61 (0.82-3.20) .17
DQ of infants with moderate to severe HIE
Median (range) 91 (45-112) 81 (22-107) .04
DQ<70 (%) 4/56 (7%) 13/48 (27%) 0.21 (0.06-0.69) .01
DQ 70-84 (%) 17/56 (31%) 10/48 (21%) 1.70 (0.69-4.19) .27
DQ$85 (%) 35/56 (62%) 25/48 (52%) 1.53 (0.70-3.36) .32
*5 of 80 survival cases in selective head cooling group (6.2%) and 4 of survival 67 cases (6%) in control group did not have the Gesell development score
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in the control groups, P = .02 (Table III).Correlation Between Death or Severe Disability and
Sex, Fever, and Seizure in Infants with Moderate to
Severe HIE
Fever was defined as temperature > 38.0C at least once to an
age of 96 hours. Eleven infants (5 and 6 infants in the selective
head cooling and control group) had a fever. The hypother-
mia occurred during the rewarming period in the 5 infants in
the selective head cooling group. In the control group, 2, 1, 2,
and 1 infant had a fever within the first 24 hours, 24 to 48
hours, 48 to 72 hours, and 72 to 96 hours, respectively. Sei-
zures were diagnosed clinically. Forty-nine infants (33 and
16 infants before treatment and during treatment, respec-
tively) and 44 infants (30 and 14 infants before treatment
and during treatment, respectively) had a seizure in the selec-
tive head cooling and control groups, respectively. The rate of
death and major disability among infants with fever, seizures,
and male sex, respectively, was 5/13 (38%), 22/49 (45%), and
27/70 (39%) in the selective head cooling group and 6/14
(43%), 27/44 (61%) and37/62 (60%) in the control group.
Multinomial logistic regression showed no correlation be-
tween death or severe disability and fever, seizures, and sex
(P = .99, P = .37, P = .50, respectively).Death and Causes of Death
The mortality rate was no significant different between the
selective head cooling and control group (Table III).
Severe encephalopathy, respiratory failure, kidney failure,
and severe hemorrhage were the major causes of death, and
most infants died during the first week in both groups
(Table II).370Discussion
Hypothermia, whether whole body or selective head cool-
ing, shows great promise on the basis of both animal and
human neonatal studies.3,4,11-15 Three RCT trials demon-
strated that hypothermia could improve the combined out-
come of death and severe neurodevelopmental disability or
an increased rate of survival without neurologic abnormal-
ity and reduced risks of cerebral palsy at 18 months of
age.16-18 A recently published meta-analysis32 also showed
the effectiveness of hypothermia for improving the com-
bined outcome of death and neurodevelopment disability
after hypoxic ischemic injury. We also found that selective
head cooling titrated to a nasopharyngeal temperature of
34C combined with mild whole-body hypothermia (rectal
temperature 34.5 to 35C) within 6 hours after delivery
had a significant brain-protective effect compared with nor-
mothermia. The combined outcome of death and severe
disability at 18 months for all infants with HIE was signif-
icantly decreased in the selective head cooling group com-
pared with the control group.
Hypothermia may be most effective for infants with mod-
erate HIE.16-18,32 We found a statistically significant benefit
of selective head cooling for infants with moderate HIE and
a trend for significance among infants with severe HIE.
Fever and clinically defined seizures are important factors
that may influence outcome among infants with HIE.33-36
Multinomial logistic regression demonstrated no effect on fe-
ver and seizures outcome in our study. The incidence of sei-
zures was similar in both groups (49% and 47% in the
selective head cooling group and in the control group, re-
spectively). These results suggest that hypothermia may not
avert the onset of seizures.Zhou et al
September 2010 ORIGINAL ARTICLESWe found no significant increase in adverse events such as
arrhythmia, major venous thrombosis, moderate to severe
scleredema, refractory hypotension, hemorrhage, thrombo-
cytopenia, disseminated intravascular coagulation, or pul-
monary hypertension with hypothermia. Indicators of
hepatic and renal function and metabolic homeostasis in
the selective head cooling group were not different from
the control group. There were 2 infants (1.7%) with mild
scleredema during hypothermia who recovered after re-
warming.
There were several limitations to our study. Despite our
best efforts, a significant proportion of our infants were
lost to follow-up (16% vs 19% in the selective head cooling
and control group, respectively). Second, male infants were
the larger proportion in the study. In this study, there was
no effect of sex on the outcome in our study.
Our inclusion criteria included all infants with HIE, in-
cluding those with mild HIE (21% in the selective head cool-
ing group and 19% in control group) and thus included
infants who may not have benefited from hypothermia.
Our results showed that infants with mild HIE in both groups
had no risk of death or major disability, confirming the ex-
clusion of this subgroup in other published studies.19,20 To
make our results more comparable with other published hy-
pothermia studies, we reported the results of subgroup anal-
yses of infants with moderate and severe HIE and found
slightly lower rates of adverse outcomes compared with those
previously reported. Our inclusion criteria were different
from those used in other studies.16-18 For example, Apgar
score <5 at 10 minutes was used as an inclusion criteria16-
18; in our study, an Apgar score<5 at 5 minutes was used.
Our results add to the evidence that selective head cooling
combined with mild systemic hypothermia for 72 hours can
decrease death or severe disability among infants with mod-
erate or severe HIE. Hypothermia was well tolerated without
major adverse events. Importantly, despite the limited re-
sources for research in China, our study demonstrates the
feasibility of conducting a multicentered RCT in China. n
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mortality and morbidity. Clin Perinatol 2006;33:55-63.50 Years Ago in THE JOURNAL OF PEDIATRICSSturge-Weber Syndrome; Nonsurgical Management
Smith, AG and Ramsay, AB. J Pediatr 1960;57:585-8
In 1960, the choice of anti-seizure medications was rather limited: phenytoin and phenobarbital were the mainstaysof treatment. Ethosuximide was newly available for children with absence (‘‘petit mal’’) epilepsy. Bromide salts and
the ketogenic diet were alternatives. It would be another 14 and 18 years until carbamazepine and valproic acid became
available. Phenytoin remains an effective and inexpensive anti-seizure medication; it is the most commonly prescribed
anti-seizure medication in the world.
We are fortunate in 2010 to have some 2 dozen medications we can prescribe for epilepsy; however the advantages
over older medications have little to do with greater efficacy and everything to do with apparent reduction in the risk of
adverse effects and the convenience of simpler dosing regimens.
Fifty years ago in The Journal, Smith and Ramsay described the effectiveness of adding phenobarbital (on a 4-times
per day dosing regimen) to phenytoin (3-times per day) in a child with uncontrolled seizures caused by Sturge-Weber
syndrome. The authors note the then recently described efficacy of hemipsherectomy for intractable epilepsy in chil-
dren with Sturge-Weber syndrome.1
In 2010, with so many once-a-day and twice-a-day anti-seizure medications at our disposal, we sympathize with the
parents trying to adhere (in the modern parlance) to the 2 drug/3-times-a-day/4-times-a-day regimen. But a closer
reading reveals the authors’ advocacy of solid principles we rely on today for treating children with intractable epi-
lepsy: (1) Maximizing the first medication is advisable before adding a second drug; (2) Slow titration is often well
tolerated when using a potentially sedating medication like phenobarbital; (3) Control of epilepsy may be transient,
and consideration of intervention with epilepsy surgery should be considered when reasonable medications have
failed; and (4) Behavior and cognitive symptoms are not entirely attributable to the medications and the underlying
epilepsy. Parents’ anxiety has a cost, and wise counseling by the pediatrician (and neurologist) to ‘‘avoid overprotec-
tion and to permit the patient to lead as normal a life as possible’’ is indispensable.
Donald M. Olson, MD
Departments of Neurology and Pediatrics
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Figure 1. Trial profile.
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Figure 2. Changes in nasopharyngeal, rectal temperature, and heart rate in selective head cooling and control group.
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